The global non-invasive prenatal testing market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.
The non-invasive prenatal testing market is highly consolidated in nature with several big and emerging players. Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK) are some of the key players in the market. These players have adopted various growth strategies, such as new product & service launches & upgrades; expansions; acquisitions; and partnerships, agreements, & collaborations to further expand their presence in the global market.
To know about the assumptions considered for the study download the pdf brochure
Partnerships, agreements, and collaborations have been the key growth strategies adopted by players from 2016 to 2018. Some of the leading players who adopted these strategies include PerkinElmer (US), Premaitha Health plc (UK), Natera, Inc. (US), Illumina, Inc. (US), and Thermo Fisher Scientific (US).
Illumina is one of the major players in the non-invasive prenatal testing market. The company offers a range of highly interconnected products related to sequencing, genotyping, gene expression, and molecular diagnostics. It also offers whole-genome sequencing, genotyping, NIPT, and support services which further strengthen its market position.
Over the past three years, Illumina has launched several products to sustain its leading position in the NIPT market. For this purpose, the company has invested a significant amount of its revenue on R&D expenditure. In 2018, Illumina invested 18.6% of its revenue on R&D. In January 2019, Illumina expanded its NIPT platform portfolio with the launch of its VeriSeq NIPT Solution v2.
The company also focuses on inorganic strategies with leading players in the market to co-develop advanced technologies and strengthen its research & commercialization capabilities. Illumina is expected to grow at a high rate in the NIPT market during the forecast period, owing to its strong product portfolio, product innovation capabilities, and wide geographic presence.
Thermo Fisher Scientific is one of the key players in the NIPT market. It offers an extensive range of products, including analytical instruments, reagents & consumables, software, and services for research, analysis, discovery, and diagnostics. In addition to a robust product portfolio, Thermo Fisher Scientific also has a substantial geographical presence. The firm adopts various organic and inorganic strategies in order to retain its position in the market. In line with this, in March 2016, Thermo Fisher Scientific acquired Affymetrix, Inc. (US), a leading provider of life science & molecular diagnostic products for USD 1.3 billion. This acquisition enabled the company to strengthen its bioscience & genetic analysis capabilities. The company also invests heavily in R&D activities to develop new solutions. For instance, in 2018, it invested USD 967 million in R&D activities. With its strong product portfolio and wide geographic presence, Thermo Fisher Scientific is expected to witness rapid growth in the NIPT market during the forecast period.
GE Healthcare held the third leading position in the global NIPT market in 2018. The company has a broad product portfolio for ultrasound devices. Besides this, it also has a strong geographical presence across 180 countries and a wide customer base in emerging economies. GE Healthcare focuses on product launches by developing technologically advanced ultrasound systems and software for prenatal examination. The company also focuses on inorganic strategies such as agreements, partnerships, and collaborations to ensure continuous growth in the global NIPT market. GE Healthcare launched the Voluson E10 ultrasound system, which is specifically designed for OB/GYN applications. The company’s leading position in the NIPT market can be attributed to its comprehensive product portfolio, strong global presence, and focused R&D investments.
Non Invasive Prenatal Testing (NIPT) Market by Product (Consumables, Reagent, Ultrasound, NGS, PCR, Microarray), Services, Method (cfDNA, Biochemical Markers), Application (Aneuploidy, Microdeletion) & End-User (Hospital, Labs)-Global Forecasts to 2024
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE